StockNews.com assumed coverage on shares of Ampio Pharmaceuticals (NYSE:AMPE – Free Report) in a report released on Monday morning. The firm issued a sell rating on the stock.
Ampio Pharmaceuticals Stock Down 7.9 %
AMPE stock opened at $2.40 on Monday. The company has a market cap of $1.99 million, a P/E ratio of -0.20 and a beta of 1.84. Ampio Pharmaceuticals has a twelve month low of $2.35 and a twelve month high of $13.20. The business has a fifty day moving average of $3.21 and a 200-day moving average of $4.22.
Ampio Pharmaceuticals (NYSE:AMPE – Get Free Report) last released its earnings results on Tuesday, November 14th. The company reported ($1.53) earnings per share for the quarter.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in AMPE. BlackRock Inc. boosted its position in shares of Ampio Pharmaceuticals by 0.4% during the first quarter. BlackRock Inc. now owns 13,996,074 shares of the company’s stock worth $6,578,000 after buying an additional 61,269 shares during the period. State Street Corp boosted its position in shares of Ampio Pharmaceuticals by 2.0% during the first quarter. State Street Corp now owns 3,430,770 shares of the company’s stock worth $1,612,000 after buying an additional 66,375 shares during the period. Vanguard Group Inc. boosted its position in shares of Ampio Pharmaceuticals by 0.8% during the first quarter. Vanguard Group Inc. now owns 9,307,338 shares of the company’s stock worth $4,375,000 after buying an additional 77,822 shares during the period. Price T Rowe Associates Inc. MD boosted its position in shares of Ampio Pharmaceuticals by 73.5% during the second quarter. Price T Rowe Associates Inc. MD now owns 394,100 shares of the company’s stock worth $66,000 after buying an additional 166,979 shares during the period. Finally, HRT Financial LP raised its holdings in Ampio Pharmaceuticals by 1,399.2% during the first quarter. HRT Financial LP now owns 217,052 shares of the company’s stock worth $50,000 after acquiring an additional 202,574 shares in the last quarter. 3.10% of the stock is owned by institutional investors and hedge funds.
About Ampio Pharmaceuticals
(Get Free Report)
Ampio Pharmaceuticals, Inc, a biopharmaceutical company, develops therapies for the treatment of osteoarthritis-related pain. It focuses on the preclinical development of AR-300, a novel proprietary, small molecule formulation for the treatment of osteoarthritis of the knee. The company is headquartered in Englewood, Colorado.
Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.